Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases

Mu, Xiaoqian; Zhang, Meng; Wei, Anhui; Yin, Fei; Wang, Yan; Hu, Kebang; Jiang, Jinlan

doi:10.1039/d0nr08024a

Cited by 78 publications

(49 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to the control group, average tumor weights in the PTX-NPs treatment group decreased significantly (* p < 0.05) as did tumor weights in the PTX-siRNA VEGF -NPs treatment group (** p < 0.01) ( Figure 7D ). These findings were comparable to those reported by Mu et al 45 , who evaluated combined in vivo anti-tumor effects of DOX and PD-L1 siRNA co-loaded with multifunctional NPs. Compared to PBS treated groups, free DOX and DOX-loaded NPs moderately inhibited tumor growth.…”

Section: Resultssupporting

confidence: 91%

See 1 more Smart Citation

Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice

Jin¹,

Hou²,

Quan³

et al. 2021

IJN

View full text Add to dashboard Cite

Background The dual-loaded nano-delivery system can realize chemotherapeutic drug and small interfering RNA (siRNA) co-loading as well as enhance the therapeutic effect of drugs on tumors through a synergistic effect, while reducing their toxic and side effects on normal tissues. Methods Previously, we developed layered smart nanoparticles (NPs) to co-deliver survivin siRNA as well as small molecule drugs for lung cancer. In this study, we used such smart NPs to co-deliver paclitaxel (PTX) and siRNA against vascular endothelial growth factor (VEGF) gene for breast cancer therapy in mice models. For the prepared NPs, characterizations such as particle size, zeta potential, gel electrophoresis imaging and in vitro stability were investigated. Then, 4T1 cells were used to evaluate the in vitro VEGF silencing capacity, tumor cell inhibitory and anti-apoptotic abilities. Finally, an orthotopic model of mouse breast cancer was established to evaluate the in vivo antitumor effects and safety properties of PTX-siRNA VEGF -NPs. Results We prepared PTX-siRNA VEGF -NPs with particle size of 85.25 nm, PDI of 0.261, and zeta potential of 5.25 mV. The NPs with VEGF siRNA effectively knocked down the expression of VEGF mRNA. Cell counting kit-8 (CCK-8) and apoptosis assays revealed that the PTX-siRNA VEGF -NPs exhibited antiproliferation effect of PTX on 4T1 cells. The in vivo anti-tumor study indicated that PTX-siRNA VEGF -NPs could exert an antitumor effect by inhibiting the formation and development of new blood vessels in tumor tissues, thereby cutting off nutrient and blood supplies required for tumor tissue growth. Both the anti-tumor efficacy and in vivo safety of the PTX-siRNA VEGF -NPs group were better than that of the PTX-NPs and siRNA VEGF -NPs groups. Conclusion The combination of PTX and VEGF siRNA exerts good antitumor effect on 4T1 tumor cells. This study provides a theoretical and practical basis for breast cancer therapy.

show abstract

Section: Resultssupporting

confidence: 91%

“…25 7D). These findings were comparable to those reported by Mu et al 45 , who evaluated combined in vivo anti-tumor effects of DOX and PD-L1 siRNA coloaded with multifunctional NPs. Compared to PBS treated groups, free DOX and DOX-loaded NPs moderately inhibited tumor growth.…”

Section: In Vivo Anticancer Efficacy Effects On Tumor Size and Weightssupporting

confidence: 91%

Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice

Jin¹,

Hou²,

Quan³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…Surface modifications with antitumor coatings are important strategies for optimizing Ti6Al4V scaffolds. A coating with antitumor drugs, such as doxorubicin, PD-L1, and other targeted drugs, has been found to be effective [ [36] , [37] , [38] ]. Unfortunately, due to the surface inertness of titanium alloys, the direct binding of drugs on their surface is difficult.…”

Section: Discussionmentioning

confidence: 99%

Biofunctional magnesium-coated Ti6Al4V scaffolds promote autophagy-dependent apoptosis in osteosarcoma by activating the AMPK/mTOR/ULK1 signaling pathway

Wei

Tang

et al. 2021

Materials Today Bio

View full text Add to dashboard Cite

The recurrence of osteosarcoma (OS) after reconstruction using Ti6Al4V prostheses remains a major problem in the surgical treatment of OS. Modification of the surfaces of Ti6Al4V prostheses with antitumor functions is an important strategy for improving therapeutic outcomes. Magnesium (Mg) coating has been shown to be multifunctional: it exhibits osteogenic and angiogenic properties and the potential to inhibit OS. In this study, we determined the proper concentration of released Mg 2+ with respect to OS inhibition and biosafety and evaluated the anti-OS effects of Mg-coated Ti6Al4V scaffolds. We found that the release of Mg 2+ during short-term and long-term degradation could significantly inhibit the proliferation and migration of HOS and 143B cells. Increased cell apoptosis and excessive autophagy were also observed, and further evidence of AMPK/mTOR/ULK1 signaling pathway activation was obtained both in vitro and in vivo , which suggested that the biofunctional scaffolds induce OS inhibition. Our study demonstrates the ability of an Mg coating to inhibit OS and may contribute to the further application of Mg-coated Ti6Al4V prostheses.

show abstract

“…With a similar active combination, doxorubicin and PD-L1 siRNA, Mu et al recruited stem cell membrane-coated polydopamine NPs (PDA–DOX/siPD-L1@SCM) as the delivery carrier. PDA–DOX/siPD-L1@SCM performed a great efficacy in PCa bone metastases by the synergistic effect [ 31 ]. In another work, doxorubicin and PD-L1 siRNA were loaded into a stimuli-responsive polymer with a poly-L-lysine–lipoic acid reduction-sensitive core and a tumour extracellular pH-stimulated shedding polyethylene glycol layer.…”

Section: Nanoparticles: a Novel Concept For Enhanced Cancer Treatment...mentioning

confidence: 99%

Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology

Tran

2022

R. Soc. open sci.

View full text Add to dashboard Cite

Although nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval. Can nanotechnology be a realistic tool to reduce the number of hospital beds? At present, several clinically approved anti-PD-1/PD-L1 antibodies or CAR T cell-based therapies are available; however, the immunotherapy field is far from mature. Will immunotherapy be the fourth pillar of cancer treatment? In this review, we summarized the current status of immunotherapy using PD-1/PD-L1-targeting nanocarriers. The knowledge on material science, therapeutic agents and formulation designs could pave the way for high-efficacy treatment outcomes.

show abstract

Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases

Abstract: Polydopamine nanoparticles camouflaged with stem cell membranes could effectively target tumor sites and showed excellent performance in synergistic chemoimmunotherapy for PCa bone metastases.

Cited by 78 publications

References 22 publications

Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice

Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice

Biofunctional magnesium-coated Ti6Al4V scaffolds promote autophagy-dependent apoptosis in osteosarcoma by activating the AMPK/mTOR/ULK1 signaling pathway

Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology

Contact Info

Product

Resources

About